Insider · CIK 0002041300
Hankil Yoon
Files at APUS (Apimeds Pharmaceuticals US, Inc.). First filing -, latest -.
In brief
Hankil Yoon files SEC Form 4 as director at APUS (Apimeds Pharmaceuticals US, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Hankil Yoon has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 11, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | AGrant or award Stock Option (right to buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Nov 13, 2025 |
| Oct 15, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | AGrant or award Stock Option (right to buy)derivative | +3,000 | $0.00 | $0 | 3,000 | Oct 17, 2025 |
| May 16, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | AGrant or award Stock Option (right to buy)derivative | +5,780 | $0.00 | $0 | 5,780 | May 20, 2025 |
Questions about Hankil Yoon
Answered from the filings on this page, as of the latest one.
Is Hankil Yoon buying or selling?
Hankil Yoon has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Hankil Yoon's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Hankil Yoon has 0.
Where does Hankil Yoon file Form 4?
Hankil Yoon has filed Form 4 at APUS (Apimeds Pharmaceuticals US, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.